BACKGROUND: Identification of real-time adverse drug reactions [ADRs] (as opposed to the risk of ADRs) in older poly-medicated people in primary care is a challenging task, often undertaken without an explicit strategy. This systematic review aims to evaluate replicable instruments and methods for identifying and addressing ADRs. METHODS: A systematic search was conducted in Medline, CINAHL, Scopus, Web of Science and Cochrane library, using controlled vocabulary (MeSH) and free-text terms. Randomised controlled trials (RCTs) implementing strategies to identify or resolve ADRs experienced by patients in primary care were included. Two reviewers independently screened studies, extracted data, and assessed the risk of bias using the Cochrane Risk of Bias tool. Discrepancies were resolved by discussion. RESULTS: From 2,182 unique records, 49 studies were identified for full review. Eight papers reporting results from 6 RCTs were included. All six trials utilised a list of medicine-related unwanted symptoms to identify ADRs. Two of three studies using adverse drug reaction questionnaires reported statistically significant increased rates of ADR reporting. Two of three studies that combined symptom questionnaires with prescriber consultations reported reductions in the number of health problems. Overall, results suggest that the three studies that described multidisciplinary collaborations using lists of ADRs plus prescriber reviews enhanced patient safety. However, the RCTs were unblinded and reported suboptimal retention. When considered as a whole, findings are equivocal and the data are too heterogenous to warrant any firm conclusions, beyond the need for more research to optimise strategies to safeguard patient wellbeing. IMPLICATIONS: Adaptable and scalable instruments with decision support are needed in primary care to identify and mitigate medicine-related harm in older poly-medicated people. The effectiveness of adverse drug reaction identification instruments, the value of comprehensive instruments, and the optimum method of delivery should be explored in multicentre trials.

Department of Nursing Faculty of Health and Social Studies University of South Bohemia Ceske Budejovice Czechia

Faculty of Medicine Health and Life Sciences Swansea University Swansea United Kingdom

Zobrazit více v PubMed

World Health Organisanisation. Medication without harm. WHO global patient safety challenge; 2017 [cited 2021 Nov 7]. Available from https://apps.who.int/iris/bitstream/handle/10665/255263/WHO-HIS-SDS-2017.6-eng.pdf?sequence=1

Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356(9237):1255–9. doi: 10.1016/S0140-6736(00)02799-9 PubMed DOI

Gyllensten H, Rehnberg C, Jönsson AK, Petzold M, Carlsten A, Andersson Sundell K. Cost of illness of patient-reported adverse drug events: a population-based cross-sectional survey. BMJ Open. 2013;3(6):e002574. doi: 10.1136/bmjopen-2013-002574 PubMed DOI PMC

Jennings ELM, Murphy KD, Gallagher P, O’Mahony D. In-hospital adverse drug reactions in older adults; prevalence, presentation and associated drugs-a systematic review and meta-analysis. Age Ageing. 2020;49(6):948–58. doi: 10.1093/ageing/afaa188 PubMed DOI

Sakiris MA, Sawan M, Hilmer SN, Awadalla R, Gnjidic D. Prevalence of adverse drug events and adverse drug reactions in hospital among older patients with dementia: a systematic review. Br J Clin Pharmacol. 2021;87(2):375–85. doi: 10.1111/bcp.14417 PubMed DOI

Haerdtlein A, Debold E, Rottenkolber M, Boehmer AM, Pudritz YM, Shahid F, et al.. Which adverse events and which drugs are implicated in drug-related hospital admissions? A systematic review and meta-analysis. J Clin Med. 2023;12(4):1320. doi: 10.3390/jcm12041320 PubMed DOI PMC

Elliott RA, Camacho E, Jankovic D, Sculpher MJ, Faria R. Economic analysis of the prevalence and clinical and economic burden of medication error in England. BMJ Qual Saf. 2021;30(2):96–105. doi: 10.1136/bmjqs-2019-010206 PubMed DOI

Davies J, Cooper RE, Moncrieff J, Montagu L, Rae T, Parhi M. The costs incurred by the NHS in England due to the unnecessary prescribing of dependency-forming medications. Addict Behav. 2022;125:107143. doi: 10.1016/j.addbeh.2021.107143 PubMed DOI

Salisbury H. Helen Salisbury: is transactional care enough? BMJ. 2020;368:m226. doi: 10.1136/bmj.m226 PubMed DOI

Turner A, Morris R, Rakhra D, Stevenson F, McDonagh L, Hamilton F, et al.. Unintended consequences of online consultations: a qualitative study in UK primary care. Br J Gen Pract. 2022;72(715):e128–37. doi: 10.3399/BJGP.2021.0426 PubMed DOI PMC

García-Abeijon P, Costa C, Taracido M, Herdeiro MT, Torre C, Figueiras A. Factors associated with underreporting of adverse drug reactions by health care professionals: a systematic review update. Drug Saf. 2023;46(7):625–36. doi: 10.1007/s40264-023-01302-7 PubMed DOI PMC

Gray SL, Perera S, Soverns T, Hanlon JT. Systematic review and meta-analysis of interventions to reduce adverse drug reactions in older adults: an update. Drugs Aging. 2023;40(11):965–79. doi: 10.1007/s40266-023-01064-y PubMed DOI PMC

Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017;17(1):230. doi: 10.1186/s12877-017-0621-2 PubMed DOI PMC

Sirois C, Domingues NS, Laroche M-L, Zongo A, Lunghi C, Guénette L, et al.. Polypharmacy definitions for multimorbid older adults need stronger foundations to guide research, clinical practice and public health. Pharmacy (Basel). 2019;7(3):126. doi: 10.3390/pharmacy7030126 PubMed DOI PMC

Frazier SC. Health outcomes and polypharmacy in elderly individuals: an integrated literature review. J Gerontol Nurs. 2005;31(9):4–11. doi: 10.3928/0098-9134-20050901-04 PubMed DOI

Avery A, Barber N, Ghaleb M, Franklin BD, Armstrong S, Crowe S et al.. Investigating the prevalence and causes of prescribing errors in general practice: the PRACtICe study. London: General Medical Council; 2012. Available from: https://www.rpharms.com/Portals/0/Documents/Old%20news%20documents/news%20downloads/gmc-report.pdf

Payne RA, Abel GA, Avery AJ, Mercer SW, Roland MO. Is polypharmacy always hazardous? A retrospective cohort analysis using linked electronic health records from primary and secondary care. Br J Clin Pharmacol. 2014;77(6):1073–82. doi: 10.1111/bcp.12292 PubMed DOI PMC

Prasad N, Lau ECY, Wojt I, Penm J, Dai Z, Tan ECK. Prevalence of and risk factors for drug-related readmissions in older adults: a systematic review and meta-analysis. Drugs Aging. 2024;41(1):1–11. doi: 10.1007/s40266-023-01076-8 PubMed DOI PMC

Guthrie B, Makubate B, Hernandez-Santiago V, Dreischulte T. The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995-2010. BMC Med. 2015;13:74. doi: 10.1186/s12916-015-0322-7 PubMed DOI PMC

Khezrian M, McNeil CJ, Murray AD, Myint PK. An overview of prevalence, determinants and health outcomes of polypharmacy. Ther Adv Drug Saf. 2020;11:2042098620933741. doi: 10.1177/2042098620933741 PubMed DOI PMC

Jordan S, Gabe M, Newson L, Snelgrove S, Panes G, Picek A, et al.. Medication monitoring for people with dementia in care homes: the feasibility and clinical impact of nurse-led monitoring. ScientificWorldJournal. 2014;2014:843621. doi: 10.1155/2014/843621 PubMed DOI PMC

Hughes D, Jordan M, Logan PA, Willson A, Snelgrove S, Storey M, et al.. Looking for the “Little Things”: a multi-disciplinary approach to medicines monitoring for older people using the ADRe resource. Geriatrics (Basel). 2020;5(4):79. doi: 10.3390/geriatrics5040079 PubMed DOI PMC

Alldred DP, Kennedy M-C, Hughes C, Chen TF, Miller P. Interventions to optimise prescribing for older people in care homes. Cochrane Database Syst Rev. 2016;2(2):CD009095. doi: 10.1002/14651858.CD009095.pub3 PubMed DOI PMC

Jordan S, Tunnicliffe C, Sykes A. Minimizing side-effects: the clinical impact of nurse-administered “side-effect” checklists. J Adv Nurs. 2002;37(2):155–65. doi: 10.1046/j.1365-2648.2002.02064.x PubMed DOI

Jordan S, Logan V, Turner A, Hughes D. Using nurse-led patient monitoring to avoid medicines-related harm. Nurs Stand. 2021;36(7):61–6. doi: 10.7748/ns.2021.e11770 PubMed DOI

Lim R, Ellett LK, Roughead EE, Cheah PY, Masnoon N. Patient-reported questionnaires to identify adverse drug reactions: a systematic review. Int J Environ Res Public Health. 2021;18(22):11877. PubMed PMC

Atmaja DS, Yulistiani, Suharjono, Zairina E. Detection tools for prediction and identification of adverse drug reactions in older patients: a systematic review and meta-analysis. Sci Rep. 2022;12(1):13189. doi: 10.1038/s41598-022-17410-w PubMed DOI PMC

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi: 10.1136/bmj.n71 PubMed DOI PMC

Logan V, Jordan S, Hughes D, Turner A. Methods of adverse drug reaction identification in adult service users living in their own homes: a systematic review. PROSPERO; 2022. p. CRD42022322374. Available from: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022322374

Logan V, Jordan S, Hughes D, Turner A. Methods of adverse drug reaction identification in adult service users living in theirown homes: a systematic review search strategy. Available from: https://www.crd.york.ac.uk/PROSPEROFILES/322374_STRATEGY_20220331.pdf

World Health Organisanisation. Medication safety in polypharmacy. 2019 [cited 2021 Nov 10]. Available from: https://apps.who.int/iris/bitstream/handle/10665/325454/WHO-UHC-SDS-2019.11-eng.pdf?ua=1

Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. doi: 10.1136/bmj.l4898 PubMed DOI

Eldridge S, Campell MK, Drahota AK, Giraudeau B, Reeves BC, Siegfried N, Higgins JPT. Revised Cochrane risk-of-bias tool for cluster-randomized trials (RoB 2 CRT). 2021 [cited 2023 Sept 12]. Available from: https://drive.google.com/file/d/1a7HtfocC74obX1NfW5YnKS0-4pEmis92/view

Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al.. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383–94. doi: 10.1016/j.jclinepi.2010.04.026 PubMed DOI

Schünemann H, Brożek J, Guyatt T, Oxman A. GRADE handbook. 2013. [cited 2023 Aug 2]. Available from: https://gdt.gradepro.org/app/handbook/handbook.html

Kanellopoulou A, Tsokani S. Handling heterogeneity in Cochrane reviews. 2023 [cited 2023 May 25]. Available from: https://training.cochrane.org/msu-web-clinic-april-2023

Verdoorn S, Blom J, Vogelzang T, Kwint H-F, Gussekloo J, Bouvy ML. The use of goal attainment scaling during clinical medication review in older persons with polypharmacy. Res Social Adm Pharm. 2019;15(10):1259–65. doi: 10.1016/j.sapharm.2018.11.002 PubMed DOI

Verdoorn S, Kwint H-F, Blom JW, Gussekloo J, Bouvy ML. Effects of a clinical medication review focused on personal goals, quality of life, and health problems in older persons with polypharmacy: a randomised controlled trial (DREAMeR-study). PLoS Med. 2019;16(5):e1002798. doi: 10.1371/journal.pmed.1002798 PubMed DOI PMC

Schoenmakers TWA, Teichert M, Wensing M, de Smet PAGM. Evaluation of potentially drug-related patient-reported common symptoms assessed during clinical medication reviews: a cross-sectional observational study. Drug Saf. 2017;40(5):419–30. doi: 10.1007/s40264-017-0504-7 PubMed DOI PMC

Schoenmakers TWA, Wensing M, De Smet PAGM, Teichert M. Patient-reported common symptoms as an assessment of interventions in medication reviews: a randomised, controlled trial. Int J Clin Pharm. 2018;40(1):126–34. doi: 10.1007/s11096-017-0575-7 PubMed DOI PMC

Schiff GD, Klinger E, Salazar A, Medoff J, Amato MG, John Orav E, et al.. Screening for adverse drug events: a randomized trial of automated calls coupled with phone-based pharmacist counseling. J Gen Intern Med. 2019;34(2):285–92. doi: 10.1007/s11606-018-4672-7 PubMed DOI PMC

Buchet-Poyau K, Chanelière M, Touzet S, Figon S, Rabilloud M, Coli C. Efficiency of an interactive program for enhancing patient reporting of adverse drug events in primary care. Revue d’Épidémiologie et de Santé Publique. 2018;66:S410. doi: 10.1016/j.respe.2018.05.475 DOI

Jameson JP, VanNoord GR. Pharmacotherapy consultation on polypharmacy patients in ambulatory care. Ann Pharmacother. 2001;35(7–8):835–40. doi: 10.1345/aph.10259 PubMed DOI

Weingart SN, Carbo A, Tess A, Chiappetta L, Tutkus S, Morway L, et al.. Using a patient internet portal to prevent adverse drug events: a randomized, controlled trial. J Patient Saf. 2013;9(3):169–75. doi: 10.1097/PTS.0b013e31829e4b95 PubMed DOI

McGuinness LA, Higgins JPT. Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods. 2021;12(1):55–61. doi: 10.1002/jrsm.1411 PubMed DOI

Deaton A, Cartwright N. Understanding and misunderstanding randomized controlled trials. Soc Sci Med. 2018;210:2–21. doi: 10.1016/j.socscimed.2017.12.005 PubMed DOI PMC

Jordan S, Knight J, Pointon D. Monitoring adverse drug reactions: scales, profiles, and checklists. Int Nurs Rev. 2004;51(4):208–21. doi: 10.1111/j.1466-7657.2004.00251.x PubMed DOI

Lawless J, Toronto CE, Grammatica GL. Health literacy and information literacy: a concept comparison. RSR. 2016;44(2):144–62. doi: 10.1108/rsr-02-2016-0013 DOI

Skivington K, Matthews L, Simpson SA, Craig P, Baird J, Blazeby JM, et al.. Framework for the development and evaluation of complex interventions: gap analysis, workshop and consultation-informed update. Health Technol Assess. 2021;25(57):1–132. doi: 10.3310/hta25570 PubMed DOI PMC

Avery AJ, Rodgers S, Cantrill JA, Armstrong S, Cresswell K, Eden M, et al.. A pharmacist-led information technology intervention for medication errors (PINCER): a multicentre, cluster randomised, controlled trial and cost-effectiveness analysis. Lancet. 2012;379(9823):1310–9. doi: 10.1016/S0140-6736(11)61817-5 PubMed DOI PMC

Rankin A, Cadogan C, Patterson S, Kerse N, Cardwell C, Bradley M. Interventions to improve the appropriate use of polypharmacy for older people. Cochrane Database Syst Rev. 2018;2018(9):CD008165–CD008165. PubMed PMC

Holland R, Bond C, Alldred DP, Arthur A, Barton G, Birt L, et al.. Evaluation of effectiveness and safety of pharmacist independent prescribers in care homes: cluster randomised controlled trial. BMJ. 2023;380:e071883. doi: 10.1136/bmj-2022-071883 PubMed DOI PMC

Caughey GE, Tait K, Vitry AI, Shakib S. Influence of medication risks and benefits on treatment preferences in older patients with multimorbidity. Patient Prefer Adherence. 2017;11:131–40. doi: 10.2147/PPA.S118836 PubMed DOI PMC

World Health Organisation. Technical series on safer primary care: multimorbidity. 2016 [cited 2022 Feb 12]. Available from: https://www.who.int/publications/i/item/9789241511650

NICE Guidance. London: National Institute for Health and Care Excellence (NICE); 2020. [cited 2023 May 22]. Available from: https://www.nice.org.uk/guidance/ng102/evidence/evidence-review-4-signposting-and-referral-to-other-services-and-support-pdf-4909943921

Motter FR, Fritzen JS, Hilmer SN, Paniz ÉV, Paniz VMV. Potentially inappropriate medication in the elderly: a systematic review of validated explicit criteria. Eur J Clin Pharmacol. 2018;74(6):679–700. doi: 10.1007/s00228-018-2446-0 PubMed DOI

Midão L, Giardini A, Menditto E, Kardas P, Costa E. Polypharmacy prevalence among older adults based on the survey of health, ageing and retirement in Europe. Arch Gerontol Geriatr. 2018;78:213–20. doi: 10.1016/j.archger.2018.06.018 PubMed DOI

Liao P-J, Mao C-T, Chen T-L, Deng S-T, Hsu K-H. Factors associated with adverse drug reaction occurrence and prognosis, and their economic impacts in older inpatients in Taiwan: a nested case-control study. BMJ Open. 2019;9(5):e026771. doi: 10.1136/bmjopen-2018-026771 PubMed DOI PMC

Jordan S. Managing adverse drug reactions: an orphan task. J Adv Nurs. 2002;38(5):437–48. doi: 10.1046/j.1365-2648.2002.02205.x PubMed DOI